Cargando…

Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT

BACKGROUND: For hepatitis B patients who do not meet the treatment criteria recommended by guidelines, therapy decisions depend on hepatic histology. Angiopoietin-like protein 2 (Angptl2) is a mediator of chronic inflammation that contributes to extracellular matrix remodeling. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yongqiong, Zhao, Hong, Zhou, Jiyuan, Yan, Linlin, Wang, Guiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622570/
https://www.ncbi.nlm.nih.gov/pubmed/28962551
http://dx.doi.org/10.1186/s12879-017-2728-7
_version_ 1783267937787838464
author Deng, Yongqiong
Zhao, Hong
Zhou, Jiyuan
Yan, Linlin
Wang, Guiqiang
author_facet Deng, Yongqiong
Zhao, Hong
Zhou, Jiyuan
Yan, Linlin
Wang, Guiqiang
author_sort Deng, Yongqiong
collection PubMed
description BACKGROUND: For hepatitis B patients who do not meet the treatment criteria recommended by guidelines, therapy decisions depend on hepatic histology. Angiopoietin-like protein 2 (Angptl2) is a mediator of chronic inflammation that contributes to extracellular matrix remodeling. The aim of this study was to explore the predictive value of Angptl2 as a novel biomarker of liver histology. METHODS: Hepatitis B patients with normal to minimally raised ALT were recruited. Serum Angptl2 concentrations were detected using commercial ELISA kit. The fibrosis score were assessed according to Ishak criteria. Significant fibrosis was defined as ISHAK score ≥ 3. RESULTS: Of 460 patients, 223 cases served as training cohort and 237 ones as validation cohort. Serum Angptl2 concentration was significantly associated with fibrosis scores in both training and validation group. Angptl2 combined index (ACI) for assessing significant fibrosis was developed from training cohort, based on Angptl2 and conventional variables. ACI showed areas under receiver-operating characteristic curve (AUC) of 0.835 for predicting significant fibrosis, which was superior to APRI (AUC = 0.776, P = 0.049), FIB-4 (AUC = 0.750, P = 0.010), Hui model (AUC = 0.756, P = 0.028), and had a better trend than Forn’s index (AUC = 0.796, P = 0.083) in training cohort. Finally, validation cohort revealed its robustness and reliability. CONCLUSION: Higher Angptl2 level represents as a potential biomarker independently associated with fibrosis stages. Compared with APRI, Hui model, FIB-4, Forn’s index, ACI did better in diagnosing significant fibrosis in hepatitis B patients. TRIAL REGISTRATION: The complete clinical trials protocol is available by request at clinicaltrials.gov (NCT01962155) and chictr.org (ChiCTR-DDT-13003724). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-017-2728-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5622570
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56225702017-10-12 Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT Deng, Yongqiong Zhao, Hong Zhou, Jiyuan Yan, Linlin Wang, Guiqiang BMC Infect Dis Research Article BACKGROUND: For hepatitis B patients who do not meet the treatment criteria recommended by guidelines, therapy decisions depend on hepatic histology. Angiopoietin-like protein 2 (Angptl2) is a mediator of chronic inflammation that contributes to extracellular matrix remodeling. The aim of this study was to explore the predictive value of Angptl2 as a novel biomarker of liver histology. METHODS: Hepatitis B patients with normal to minimally raised ALT were recruited. Serum Angptl2 concentrations were detected using commercial ELISA kit. The fibrosis score were assessed according to Ishak criteria. Significant fibrosis was defined as ISHAK score ≥ 3. RESULTS: Of 460 patients, 223 cases served as training cohort and 237 ones as validation cohort. Serum Angptl2 concentration was significantly associated with fibrosis scores in both training and validation group. Angptl2 combined index (ACI) for assessing significant fibrosis was developed from training cohort, based on Angptl2 and conventional variables. ACI showed areas under receiver-operating characteristic curve (AUC) of 0.835 for predicting significant fibrosis, which was superior to APRI (AUC = 0.776, P = 0.049), FIB-4 (AUC = 0.750, P = 0.010), Hui model (AUC = 0.756, P = 0.028), and had a better trend than Forn’s index (AUC = 0.796, P = 0.083) in training cohort. Finally, validation cohort revealed its robustness and reliability. CONCLUSION: Higher Angptl2 level represents as a potential biomarker independently associated with fibrosis stages. Compared with APRI, Hui model, FIB-4, Forn’s index, ACI did better in diagnosing significant fibrosis in hepatitis B patients. TRIAL REGISTRATION: The complete clinical trials protocol is available by request at clinicaltrials.gov (NCT01962155) and chictr.org (ChiCTR-DDT-13003724). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-017-2728-7) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-29 /pmc/articles/PMC5622570/ /pubmed/28962551 http://dx.doi.org/10.1186/s12879-017-2728-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Deng, Yongqiong
Zhao, Hong
Zhou, Jiyuan
Yan, Linlin
Wang, Guiqiang
Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT
title Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT
title_full Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT
title_fullStr Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT
title_full_unstemmed Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT
title_short Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT
title_sort angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis b patients with normal to minimally raised alt
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622570/
https://www.ncbi.nlm.nih.gov/pubmed/28962551
http://dx.doi.org/10.1186/s12879-017-2728-7
work_keys_str_mv AT dengyongqiong angiopoietinlikeproteinasanovelmarkerforliverfibrosisinchronichepatitisbpatientswithnormaltominimallyraisedalt
AT zhaohong angiopoietinlikeproteinasanovelmarkerforliverfibrosisinchronichepatitisbpatientswithnormaltominimallyraisedalt
AT zhoujiyuan angiopoietinlikeproteinasanovelmarkerforliverfibrosisinchronichepatitisbpatientswithnormaltominimallyraisedalt
AT yanlinlin angiopoietinlikeproteinasanovelmarkerforliverfibrosisinchronichepatitisbpatientswithnormaltominimallyraisedalt
AT wangguiqiang angiopoietinlikeproteinasanovelmarkerforliverfibrosisinchronichepatitisbpatientswithnormaltominimallyraisedalt
AT angiopoietinlikeproteinasanovelmarkerforliverfibrosisinchronichepatitisbpatientswithnormaltominimallyraisedalt